Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ventolin capsule price?Takhzyro loss of exclusivity?Tonmya fibromyalgia approval status 2026?Prialt generic approval fda?Leuprolide acetate patent?
See the DrugPatentWatch profile for pembrolizumab
Pembrolizumab binds to the programmed death-1 (PD-1) protein on T cells, blocking the PD-1 pathway. This helps T cells remain active against cancer cells. [1]
Pembrolizumab’s binding target is PD-1, not PD-L1. (Other immunotherapies may target PD-L1, but pembrolizumab specifically binds PD-1.) [1]
Drug labeling and references describing pembrolizumab’s mechanism of action identify PD-1 as its binding target. [1]
[1] https://www.drugs.com/pembrolizumab.html
Other Questions About Pembrolizumab :